Healthcare Economist October 25, 2024
Randomized controlled trials are the gold standard for evaluating treatment efficacy, but effectiveness in the real-world may vary. One reason for this is that clinical trials often have stricter inclusion criteria than is the case for the target treated population. Policymakers, payers, and clinicians may wonder how well the results from the narrower clinical trial population translate to the real-world ‘target’ population.
This is the question a paper by Lugo-Palacios et al. (2024) aims to answer. The goal of their study is to determine which second-line treatment for type 2 diabetes is most effective in the real world. To do this, the authors estimate the average treatment effect (ATEs) and conditional average treatment effect (CATE) for the use of dipeptidyl...
Today's Sponsors
Today's Sponsor